Compare CLMT & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLMT | NNVC |
|---|---|---|
| Founded | 1916 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 24.7M |
| IPO Year | 2006 | N/A |
| Metric | CLMT | NNVC |
|---|---|---|
| Price | $19.62 | $1.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $20.45 | N/A |
| AVG Volume (30 Days) | ★ 550.5K | 359.6K |
| Earning Date | 11-07-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,048,000,000.00 | N/A |
| Revenue This Year | $0.16 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.68 | $0.94 |
| 52 Week High | $23.75 | $2.23 |
| Indicator | CLMT | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 47.48 |
| Support Level | $19.17 | $1.23 |
| Resistance Level | $20.89 | $1.28 |
| Average True Range (ATR) | 0.56 | 0.11 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 36.18 | 52.38 |
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.